Plasma Hsp90 levels in patients with systemic sclerosis and relation to lung and skin involvement: a cross-sectional and longitudinal study

Scientific Reports - Tập 11 Số 1
Hana Štorkánová1, S. Oreská1, Maja Špiritović1, Barbora Heřmánková2, Kristýna Bubová1, Martin Komarc3, Karel Pavelká1, Jiří Vencovský1, Jörg H. W. Distler4, Ladislav Šenolt5, Radim Bečvář1, Michal Tomčík5
1Institute of Rheumatology, Prague, Czech Republic
2Department of Physiotherapy, Faculty of Physical Education and Sport, Charles University, Prague, Czech Republic
3Department of Methodology, Faculty of Physical Education and Sport, Charles University, Prague, Czech Republic
4Department of Internal Medicine III and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany
5Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic

Tóm tắt

AbstractOur previous study demonstrated increased expression of Heat shock protein (Hsp) 90 in the skin of patients with systemic sclerosis (SSc). We aimed to evaluate plasma Hsp90 in SSc and characterize its association with SSc-related features. Ninety-two SSc patients and 92 age-/sex-matched healthy controls were recruited for the cross-sectional analysis. The longitudinal analysis comprised 30 patients with SSc associated interstitial lung disease (ILD) routinely treated with cyclophosphamide. Hsp90 was increased in SSc compared to healthy controls. Hsp90 correlated positively with C-reactive protein and negatively with pulmonary function tests: forced vital capacity and diffusing capacity for carbon monoxide (DLCO). In patients with diffuse cutaneous (dc) SSc, Hsp90 positively correlated with the modified Rodnan skin score. In SSc-ILD patients treated with cyclophosphamide, no differences in Hsp90 were found between baseline and after 1, 6, or 12 months of therapy. However, baseline Hsp90 predicts the 12-month change in DLCO. This study shows that Hsp90 plasma levels are increased in SSc patients compared to age-/sex-matched healthy controls. Elevated Hsp90 in SSc is associated with increased inflammatory activity, worse lung functions, and in dcSSc, with the extent of skin involvement. Baseline plasma Hsp90 predicts the 12-month change in DLCO in SSc-ILD patients treated with cyclophosphamide.

Từ khóa


Tài liệu tham khảo

Denton, C. P. & Khanna, D. Systemic sclerosis. Lancet 390, 1685–1699 (2017).

Distler, J. H. W. et al. Shared and distinct mechanisms of fibrosis. Nat. Rev. Rheumatol. 15, 705–730 (2019).

Denton, C. P., Wells, A. U. & Coghlan, J. G. Major lung complications of systemic sclerosis. Nat. Rev. Rheumatol. 14, 511–527 (2018).

Khanna, D. et al. Etiology, risk factors, and biomarkers in systemic sclerosis with interstitial lung disease. Am. J. Respir. Crit. Care. Med. 201, 650–660 (2020).

Perelas, A., Silver, R. M., Arrossi, A. V. & Highland, K. B. Systemic sclerosis-associated interstitial lung disease. Lancet. Respir. Med. 8, 304–320 (2020).

Elhai, M., Avouac, J. & Allanore, Y. Circulating lung biomarkers in idiopathic lung fibrosis and interstitial lung diseases associated with connective tissue diseases: Where do we stand?. Semin. Arthritis. Rheum. https://doi.org/10.1016/j.semarthrit.2020.01.006 (2020).

Distler, J. H. et al. Review: Frontiers of antifibrotic therapy in systemic sclerosis. Arthritis. Rheumatol. 69, 257–267 (2017).

Schlesinger, M. J. Heat shock proteins. J. Biol. Chem. 256, 12111–12114 (1990).

Santoro, M. G. Heat shock factors and the control of the stress response. Biochem. Pharmacol. 59, 55–63 (2000).

Guo, J., Chang, C. & Li, W. The role of secreted heat shock protein-90 (Hsp90) in wound healing—How could it shape future therapeutics?. Expert Rev. Proteomics. 14, 665–675 (2017).

Lindquist, S. & Craig, E. A. The heat-shock proteins. Annu. Rev. Genet. 22, 631–677 (1988).

Burrows, F., Zhang, H. & Kamal, A. Hsp90 activation and cell cycle regulation. Cell Cycle 3, 1530–1536 (2004).

Echeverria, P. C. & Picard, D. Molecular chaperones, essential partners of steroid hormone receptors for activity and mobility. Biochim. Biophys. Acta. Mol. Cell. Res. 1803, 641–649 (2010).

Pearl, L. H. & Prodromou, C. Structure and in vivo function of Hsp90. Curr. Opin. Struct. Biol. 10, 46–51 (2000).

McClellan, A. J. et al. Diverse cellular functions of the Hsp90 molecular chaperone uncovered using systems approaches. Cell 131, 121–135 (2007).

Zuehlke, A. D., Moses, M. A. & Neckers, L. Heat shock protein 90: Its inhibition and function. Philos. Trans. R. Soc. B. Biol. Sci. 373, 20160527 (2018).

Tsan, M. F. & Gao, B. Cytokine function of heat shock proteins. AJP Cell. Physiol. 286, C739-744 (2004).

Bohonowych, J. E. et al. Extracellular Hsp90 mediates an NF-κB dependent inflammatory stromal program: Implications for the prostate tumor microenvironment. Prostate 74, 395–407 (2014).

Chung, S. W. et al. Extracellular heat shock protein 90 induces interleukin-8 in vascular smooth muscle cells. Biochem. Biophys. Res. Commun. 378, 444–449 (2009).

Beyer, C. & Distler, J. H. W. Tyrosine kinase signaling in fibrotic disorders. Biochim. Biophys. Acta. Mol. Basis. Dis. 1832, 897–904 (2013).

Koga, F. et al. Hsp90 inhibition transiently activates Src kinase and promotes Src-dependent Akt and Erk activation. Proc. Natl. Acad. Sci. 103, 11318–11322 (2006).

Skhirtladze, C. et al. Src kinases in systemic sclerosis: Central roles in fibroblast activation and in skin fibrosis. Arthriti. Rheum. 58, 1475–1484 (2008).

Wrighton, K. H., Lin, X. & Feng, X. H. Critical regulation of TGFbeta signaling by Hsp90. Proc. Natl. Acad. Sci. USA 105, 9244–9249 (2008).

Tomcik, M. et al. Heat shock protein 90 (Hsp90) inhibition targets canonical TGF-β signalling to prevent fibrosis. Ann. Rheum. Dis. 73, 1215–1222 (2014).

Gao, C. et al. Inhibition of heat shock protein 90 as a novel platform for the treatment of cancer. Curr. Pharm. Des. 25, 849–855 (2019).

Norton, P. M., Isenberg, D. A. & Latchman, D. S. Elevated levels of the 90 kd heat shock protein in a proportion of SLE patients with active disease. J. Autoimmun. 2, 187–195 (1989).

Bubova, K. et al. Plasma Hsp90 levels in patients with spondyloarthritis and their relation to structural changes: A cross-sectional study. Biomark. Med. https://doi.org/10.2217/bmm-2020-0360.

Storkanova, H. et al. Increased Hsp90 in muscle tissue and plasma associates with disease activity and skeletal muscle involvement in patients with idiopathic inflammatory myopathies. Ann. Rheum. Dis. 79(supplement 1), 410 (2020).

Ocaña, G. J. et al. Inflammatory stress of pancreatic beta cells drives release of extracellular heat-shock protein 90α. Immunology 151, 198–210 (2017).

Tas, F., Bilgin, E., Erturk, K. & Duranyildiz, D. Clinical significance of circulating serum cellular heat shock protein 90 (HSP90) level in patients with cutaneous malignant melanoma. Asian. Pacific. J. Cancer Prev. 18, 599–601 (2017).

Fu, Y. et al. Plasma heat shock protein 90alpha as a biomarker for the diagnosis of liver cancer: An official, large-scale, and multicenter clinical trial. E. Bio. Medicine 24, 56–63 (2017).

Shi, Y. et al. Plasma levels of heat shock protein 90 alpha associated with lung cancer development and treatment responses. Clin. Cancer. Res. 20, 6016–6022 (2014).

Muangchan, C. & Pope, J. E. The significance of interleukin-6 and C-reactive protein in systemic sclerosis: A systematic literature review. Clin. Exp. Rheumatol. 31, 122–134 (2013).

Sontake, V. et al. Hsp90 regulation of fibroblast activation in pulmonary fibrosis. JCI Insight 2, e91454 (2017).

Koh, R. Y. et al. Inhibition of transforming growth factor-β via the activin receptor-like kinase-5 inhibitor attenuates pulmonary fibrosis. Mol. Med. Rep. 11, 3808–3813 (2015).

O’Reilly, S., Cant, R., Ciechomska, M. & Van Laar, J. M. Interleukin-6: A new therapeutic target in systemic sclerosis?. Clin. Transl. Immunol. 2, e4 (2013).

Khanna, D. et al. Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): A phase 2, randomised, controlled trial. Lancet 387, 2630–2640 (2016).

Narváez, J. et al. Effectiveness and safety of tocilizumab for the treatment of refractory systemic sclerosis associated interstitial lung disease: A case series. Ann. Rheum. Dis. 78, e123 (2019).

O’Reilly, S., Ciechomska, M., Cant, R. & Van Laar, J. M. Interleukin-6 (IL-6) trans signaling drives a STAT3-dependent pathway that leads to hyperactive transforming growth factor-β (TGF-β) signaling promoting SMAD3 activation and fibrosis via gremlin protein. J. Biol. Chem. 289, 9952–9960 (2014).

Sato, N. et al. Involvement of heat-shock protein 90 in the interleukin-6-mediated signaling pathway through STAT3. Biochem. Biophys. Res. Commun. 300, 847–852 (2003).

Nannini, C., West, C. P., Erwin, P. J. & Matteson, E. L. Effects of cyclophosphamide on pulmonary function in patients with scleroderma and interstitial lung disease: A systematic review and meta-analysis of randomized controlled trials and observational prospective cohort studies. Arthritis Res. Ther. 10, R124 (2008).

Chakraborty, A., Boel, N.M.-E. & Edkins, A. L. HSP90 interacts with the fibronectin N-terminal domains and increases matrix formation. Cells 9, 272 (2020).

Van Den Hoogen, F. et al. 2013 classification criteria for systemic sclerosis: An American College of Rheumatology/European League against Rheumatism collaborative initiative. Arthritis Rheum. 65, 2737–2747 (2013).

Silver, R. M., Miller, K. S., Kinsella, M. B., Smith, E. A. & Schabel, S. I. Evaluation and management of scleroderma lung disease using bronchoalveolar lavage. Am. J. Med. 88, 470–476 (1990).

Bombardieri, S., Medsger, T. A. Jr., Silman, A. J. & Valentini, G. The assessment of the patient with systemic sclerosis. Introduction. Clin. Exp. Rheumatol. 21, S2–S4 (2003).

Clements, P. J. et al. Skin thickness score in systemic sclerosis: An assessment of interobserver variability in 3 independent studies. J. Rheumatol. 20, 1892–1896 (1993).

Valentini, G., Silman, A. J. & Veale, D. Assessment of disease activity. Clin. Exp. Rheumatol. 21, S39-41 (2003).

Crapo, O. et al. Standardization of spirometry, 1994 update. American Thoracic Society. Am. J. Respir. Crit. Care. Med. 152, 1107–1136 (1995).

Thông tin
Thông tin xuất bản

Scientific Reports

Tập 11 Số 1

Thông tin tác giả